January 17, 2018
Atlas5D is proud to announce that Solid Biosciences will utilize the company’s 24×7 real-world mobility and behavioral measurements as part of “Ignite DMD”, a phase I/II gene transfer study to investigate the safety, tolerability, and efficacy of intravenous SGT-001 in patients with Duchenne muscular dystrophy (DMD). Atlas5D’s Ambient Measurement System (AMS), dubbed Echo5D, will be placed into each patient’s home to help quantify treatment response.
Jorge Quiroz, MD, Chief Medical Officer of Solid Biosciences, said, “In the past, there has been no technology that could effectively measure clinically relevant movements in a person’s own home, without the requirement for wearables, while maintaining a patient’s privacy. If successful in capturing real-world functional data, we believe that Echo5D will help researchers to more effectively ascertain the treatment effect of clinical candidates for mobility disorders, such as DMD.”Zeb Kimmel, MD, MBA, CEO of Atlas5D, said, “We are thrilled to support Solid Biosciences in their mission to solve Duchenne muscular dystrophy, and honored that Solid placed this trust in our team and technology. Atlas5D is pioneering the high-precision measurement of real-world function with safety, convenience, and privacy. We are privileged to bring meaningful, high-impact, non-invasive results to the participants, researchers, and sponsors of Ignite DMD.”Ignite DMD is currently open for enrollment. For more information about the clinical trial, please visit www.clinicaltrials.gov.About Atlas5DAtlas5D is a leader in creating solutions to help people with reduced mobility live better and richer lives. These populations range in age from very young to very old; cover a wide variety of conditions, such as Duchenne muscular dystrophy and multiple sclerosis; and often do not or cannot use “wearable” sensors. The company’s flagship product, Echo5D, is the first ambient sensor that passively and precisely measures human movement and behavior, 24×7, even in the dark. There’s nothing to remember, no need to wear any devices, no change in lifestyle, and no photos. By providing insight and quantitative actionable information to manufacturers, clinicians, and patients, Atlas5D offers the ability to track real-world indicators of disease status and treatment response. Please visit us at www.atlas5d.com.